- Home
- CGO vs ANTX Comparison
CGO vs ANTX Comparison
Compare CGO & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGO | ANTX |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.2M | 158.8M |
| IPO Year | 2004 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CGO | ANTX |
|---|---|---|
| Price | $12.97 | $4.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 29.4K | ★ 442.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.71 | $1.00 |
| 52 Week High | $14.20 | $6.91 |
Technical Indicators
Market Signals| Indicator | CGO | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 51.33 |
| Support Level | $12.97 | $3.91 |
| Resistance Level | $13.88 | $5.13 |
| Average True Range (ATR) | 0.29 | 0.36 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 1.25 | 46.09 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.